Cyxone Selects First Clinical Site Ahead of Phase 1 Study With T20K in MS |
| October 23, 2018 | October 2018 Bond Updates |
|
STOCKHOLM, Oct. 23, 2018 /PRNewswire/ -- Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study. The clinical site located in Western Europe has been carefully evaluated based on a number of crucial ... |
| View more at: https://www.prnewswire.com:443/news-releases/cyxone-selects-first-clinical-site-ahead-of-phase-1-study-with-t20k-in-ms-300735844.html |
| Related News |